Covidien (NYSE:COV) said it won CE Mark approval in the European Union for home use of its Nellcor bedside SpO2 patient monitoring system.

Mansfield, Mass.-based Covidien’s PM100N device is designed to continuously monitor pulse rates and oxygen levels in a home-care setting, according to a press release. It features Covidien’s SatSeconds alarm management technology, which helps caregivers distinguish between serious and minor monitoring events.

The monitor can also be programmed with a password to prevent others from accidentally changing the settings. The PM100N is currently on the market in Europe, Australia and New Zealand, Covidien said.

In October, Covidien won U.S. regulatory approval for home use for the Nellcor PM10N portable SpO2 patient monitoring system.

Covidien is currently in the midst of a $43 billion mega-merger with medical device giant Medtronic (NYSE:MDT).